Novo Nordisk announced on November 18 that semaglutide reduced body mass index in children aged 6 to under 12 with obesity in its multinational STEP Young trial. The primary analysis found an estimated BMI change of -13.5 per cent at week 68, compared with +2.7 per cent among children receiving a placebo.
That analysis included participants regardless of whether they stayed on treatment. Both groups also received support for a reduced-calorie diet and increased physical activity.
The phase 3 results were presented at ObesityWeek 2026 and published in The New England Journal of Medicine. Semaglutide remains investigational for this age group and is not approved in the United States for children under 12.
Two ways of measuring the effect
Novo Nordisk’s announcement led with a separate analysis estimating the effect if all children adhered to treatment without other weight-management interventions. Under that approach, the estimated BMI change was -17.4 per cent, compared with +2.2 per cent for placebo.
The distinction matters: the primary analysis measures the effect regardless of treatment adherence, while the second estimates outcomes under idealised conditions.
More than 85 per cent of children entered the trial with class II or III severe obesity, the company said. Participants received a weekly injection of semaglutide or placebo, alongside the lifestyle support.
“Severe obesity can profoundly affect a child’s physical health, emotional well-being, and daily life. This chronic disease also increases the risk of many obesity-related complications that can emerge early and persist into adulthood. Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child’s trajectory back towards one of improving weight related health,” Ania M. Jastreboff, MD, PhD, Professor of Medicine (Endocrinology) and Pediatrics (Pediatric Endocrinology) at Yale School of Medicine and Director of the Yale Obesity Research Center (Y-Weight) said in a statement.
Safety and longer-term limits
At week 104, the analysis regardless of adherence showed an estimated BMI change of -9.4 per cent with semaglutide and +8.4 per cent with placebo. However, Novo Nordisk said the longer-term analyses were not adjusted for multiple statistical comparisons and should not be used to infer definitive treatment effects.
The company said it identified no unexpected safety concerns, including concerns about growth or pubertal development. It described the safety profile as consistent with previous semaglutide trials.
The medicine nevertheless carries a boxed warning for possible thyroid tumours, including cancer. It should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects include nausea, vomiting, diarrhoea and constipation.
Novo Nordisk said safety and efficacy for the investigational use remain unestablished, with no guarantee it will become commercially available for these children.




